Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Steve Savinoff

Epilepsy Parker, CO Medical Doctor

NPI 1114546058 CMS profile 11564773

9235 Crown Crest Blvd Ste 200, Parker, CO 80138

Open in the dashboard

General payments

$3,820

82 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steve Savinoff of Parker, CO is reported in the CMS Open Payments database as having received $3,820 across 82 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Epilepsy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,904 74
2024 General $1,767 6
2023 General $150 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steve Savinoff
  • Epilepsy median
  • Middle half of Epilepsy
  • National median

In program year 2025, general payments to Steve Savinoff were reported at $1,904. Among 324 Epilepsy profiles paid that year, the median was $366 and the middle half received between $146 and $1,396.

Show as a table
Year Steve Savinoff Epilepsy median Middle half National median
2019 $0 $280 $104–$1,161 $163
2020 $0 $148 $53–$3,065 $114
2021 $0 $202 $56–$1,377 $132
2022 $0 $294 $112–$1,733 $149
2023 $150 $313 $118–$1,315 $160
2024 $1,767 $338 $131–$1,210 $164
2025 $1,904 $366 $146–$1,396 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. NeuroPace, Inc. $1,738 7 payments
  2. AbbVie, Inc. $388 20 payments
  3. LivaNova USA, Inc. $314 4 payments
  4. SK Life Science, Inc. $227 5 payments
  5. Neurocrine Biosciences, Inc. $152 6 payments
  6. Jazz Pharmaceuticals Inc. $96 1 payment
  7. Teva Pharmaceuticals USA, Inc. $87 2 payments
  8. Neurelis, Inc. $77 3 payments
  9. Janssen Biotech, Inc. $69 3 payments
  10. Lilly USA, LLC $65 3 payments
  11. Other $606 28 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,345 80 payments
  2. Travel and Lodging $475 2 payments
Products named General payments · program years 2023–2025
  1. RNS Neurostimulator Kit $1,738 7 payments
  2. QULIPTA $352 18 payments
  3. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $305 3 payments
  4. UBRELVY $300 14 payments
  5. INGREZZA $152 6 payments
  6. Epidiolex $96 1 payment
  7. BOTOX $88 6 payments
  8. Austedo XR $87 2 payments
  9. VALTOCO $77 3 payments
  10. KISUNLA $65 3 payments
  11. Other $552 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Epilepsy in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record